生物活性：Metopimazine-d6 hydrochloride is the deuterium labeled Metopimazine (HY-116578). Metopimazine (EXP999; RP9965) is a phenothiazine, orally available, selective dopamine D2 receptor antagonist that does not penetrate the blood-brain barrier. Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone and the periphery, thereby inhibiting nausea and vomiting. Metopimazine is indicated for chemotherapy-induced nausea and vomiting, and has low central side effects due to its poor brain penetration. The use of metopimazine in acute gastroenteritis may have potential risks[1][2][3][4].
IC50 & Target：D2 Receptor
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被掺入药物分子中，主要用作药物研发过程中定量分析的示踪剂。氘化因其可能影响药物的药代动力学和代谢特征而备受关注[1]。
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Metopimazine acid-d6 hydrochloride 相关抗体:
DRD2 Antibody
Dopamine Receptor D3 Antibody (YA1742)
DOPA Decarboxylase Antibody (YA2428)
Dopamine Receptor D1 Antibody (YA3270)
Torsin 1A Antibody (YA2935)
PITX3 Antibody (YA2974)
HMBS Antibody (YA3061)
分子量：489.08
Formula：C22H21D6ClN2O4S2
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (546 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Victoire Roussel, et al. Estimating the excess of inappropriate prescriptions of anti-dopaminergic anti-emetics during acute gastroenteritis epidemics in France. Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1080-5.
 [Content Brief]
[3]. Mozgova O, et al. A new spectrophotometric method for the quantitative determination of Metopimazine based on the absorbance of its sulfoxide[J]. Chemical Papers, 2024, 78(11): 6585-6591.
[4]. Jolliet P, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res. 2007 Jul;56(1):11-7.
 [Content Brief]